Xeris Pharmaceuticals Inc. (XERS) Provides Business Update During Recent Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
November 21, 2019 6:00 AM ESTMAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE PFS launch underwayGVOKE HypoPen expected to launch July 2020CHI program shifts to Expanded AccessHAAF program discontinued based on Phase 2 results
CHICAGO, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,... More
